Related Experiment Video
Updated: Jul 9, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Role of autologous stem-cell transplantation in multiple myeloma
Michel Attal1, Jean-Luc Harousseau
1Hematology Department, Centre Hospitalier de Purpan, Place du Dr Baylac, 31059 Toulouse, France.
Abstract:
Multiple myeloma (MM) is one of the diseases in which the impact of dose intensity has been demonstrated. Consequently, in 2005 MM was the first disease for which autologous stem-cell transplantation (ASCT) was indicated in Europe and the US. However, ASCT is not curative, and most patients relapse in a median of 3 years. The introduction of novel agents such as thalidomide, bortezomib (Velcade) or lenalidomide (Revlimid) was logical to try to improve the high-dose strategy, and promising results have been reported. This article will focus on the current results of ASCT and will discuss the main research area to try to improve this strategy.
More Related Videos
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Mesenchymal Stem Cells

